articleThe Lancet OncologyOct 12, 2016BRONZE OA

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

PSPadmanee SharmaMKMargaret K. CallahanPBPetri BonoJWJoseph W. KimPSPavlina Spiliopoulou

The University of Texas MD Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

684
total citations
FWCI
97.05
Percentile
100%
References
34
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Medicine
  • Metastatic Urothelial Carcinoma
  • Nivolumab
  • Internal medicine
  • Urology
  • Adverse effect
  • Clinical endpoint
  • Discontinuation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding